JP7269249B2 - Ｉｌ２ｒベータ／共通ガンマ鎖抗体 - Google Patents

Ｉｌ２ｒベータ／共通ガンマ鎖抗体 Download PDF

Info

Publication number
JP7269249B2
JP7269249B2 JP2020544130A JP2020544130A JP7269249B2 JP 7269249 B2 JP7269249 B2 JP 7269249B2 JP 2020544130 A JP2020544130 A JP 2020544130A JP 2020544130 A JP2020544130 A JP 2020544130A JP 7269249 B2 JP7269249 B2 JP 7269249B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502116A5 (enExample
JP2021502116A (ja
Inventor
ブラウアー，ピーター
コノリー，ジョン
ホプキンス，リチャード
ライ，ジンヤン
ロウ，ジエンロン・ライオネル
タン，カー・ウァイ
ワン，チェン－イ
ヨー，ショク・ピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science, Technology and Research
Original Assignee
Agency for Science, Technology and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science, Technology and Research filed Critical Agency for Science, Technology and Research
Publication of JP2021502116A publication Critical patent/JP2021502116A/ja
Publication of JP2021502116A5 publication Critical patent/JP2021502116A5/ja
Priority to JP2023069702A priority Critical patent/JP7603738B2/ja
Application granted granted Critical
Publication of JP7269249B2 publication Critical patent/JP7269249B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020544130A 2017-11-10 2018-11-09 Ｉｌ２ｒベータ／共通ガンマ鎖抗体 Active JP7269249B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023069702A JP7603738B2 (ja) 2017-11-10 2023-04-21 Ｉｌ２ｒベータ／共通ガンマ鎖抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SG10201709289S 2017-11-10
SG10201709289S 2017-11-10
US201862652501P 2018-04-04 2018-04-04
US62/652,501 2018-04-04
US201862735347P 2018-09-24 2018-09-24
US62/735,347 2018-09-24
PCT/EP2018/080765 WO2019092181A1 (en) 2017-11-10 2018-11-09 Il2rbeta/common gamma chain antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023069702A Division JP7603738B2 (ja) 2017-11-10 2023-04-21 Ｉｌ２ｒベータ／共通ガンマ鎖抗体

Publications (3)

Publication Number Publication Date
JP2021502116A JP2021502116A (ja) 2021-01-28
JP2021502116A5 JP2021502116A5 (enExample) 2021-12-23
JP7269249B2 true JP7269249B2 (ja) 2023-05-08

Family

ID=64362498

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544130A Active JP7269249B2 (ja) 2017-11-10 2018-11-09 Ｉｌ２ｒベータ／共通ガンマ鎖抗体
JP2023069702A Active JP7603738B2 (ja) 2017-11-10 2023-04-21 Ｉｌ２ｒベータ／共通ガンマ鎖抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023069702A Active JP7603738B2 (ja) 2017-11-10 2023-04-21 Ｉｌ２ｒベータ／共通ガンマ鎖抗体

Country Status (7)

Country Link
US (3) US11739157B2 (enExample)
EP (1) EP3707162A1 (enExample)
JP (2) JP7269249B2 (enExample)
CN (2) CN111954680B (enExample)
SG (1) SG11202004172UA (enExample)
TW (1) TWI800552B (enExample)
WO (1) WO2019092181A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190367605A1 (en) * 2016-11-10 2019-12-05 Medimmune, Llc Binding Molecules Specific For ASCT2 And Uses Thereof
WO2020094836A1 (en) * 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
WO2020094834A1 (en) * 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
MX2022008770A (es) 2020-01-14 2022-10-07 Synthekine Inc Muteinas de la il2.
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
CN117136198A (zh) * 2021-04-02 2023-11-28 特尼奥生物股份有限公司 激动性抗il-2r抗体及其使用方法
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
GB202115122D0 (en) * 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
EP4426742A4 (en) * 2021-11-02 2025-12-24 Shanghai Epimab Biotherapeutics Co Ltd Anti-CD122 antibodies, anti-CD132 antibodies and associated bispecific binding proteins
CN120858116A (zh) 2023-01-06 2025-10-28 泰温治疗私人有限公司 抗原结合分子
EP4646274A1 (en) 2023-01-06 2025-11-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
WO2024174982A1 (en) * 2023-02-20 2024-08-29 Sinomab Bioscience Limited Anti-common gamma chain proteins and compositions of matter
CN117700554B (zh) * 2023-08-03 2024-07-12 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种抗人源cd132的单克隆抗体及其应用
CN118515762B (zh) * 2024-07-23 2024-11-01 北京百普赛斯生物科技股份有限公司 特异性结合il-2的抗体及其应用
WO2026033139A1 (en) * 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
CN122255271A (zh) * 2024-12-20 2026-06-23 三生国健药业（上海）股份有限公司 抗cd122抗体及其制备与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523839A (ja) 2010-04-08 2013-06-17 ジェイエヌ バイオサイエンシーズ エルエルシー Ｃｄ１２２に対する抗体
WO2017021540A1 (en) 2015-08-06 2017-02-09 Agency For Science, Technology And Research Il2rbeta/common gamma chain antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021732A1 (en) 1995-01-09 1996-07-18 Boehringer Ingelheim International Gmbh Il-2r-associated polypeptide and dna molecules coding therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU2937597A (en) * 1996-05-10 1997-12-05 Biogen, Inc. Common gamma chain blocking agents
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
RS61406B1 (sr) * 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
AU2015340056A1 (en) 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
WO2017192924A1 (en) * 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523839A (ja) 2010-04-08 2013-06-17 ジェイエヌ バイオサイエンシーズ エルエルシー Ｃｄ１２２に対する抗体
WO2017021540A1 (en) 2015-08-06 2017-02-09 Agency For Science, Technology And Research Il2rbeta/common gamma chain antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Drerup J.M., et al.，CD122-selective IL-2/anti-IL-2 complexes reduce regulatory T cell function and promote CD8+ T cell polyfunctionality for durable ovarian cancer immunotherapy，Cancer Res. (2017) Vol.77, 13_Supplement, Abstract 1608
ONCOIMMUNOLOGY (2016) Vol.5, No.3, e1102829, pp.1-8
The Journal of Immunology (2009) Vol.182, pp.4244-4254

Also Published As

Publication number Publication date
US20240052046A1 (en) 2024-02-15
CN118373912A (zh) 2024-07-23
JP7603738B2 (ja) 2024-12-20
EP3707162A1 (en) 2020-09-16
CN111954680A (zh) 2020-11-17
JP2023099051A (ja) 2023-07-11
TWI800552B (zh) 2023-05-01
US11739157B2 (en) 2023-08-29
US20240026016A1 (en) 2024-01-25
US20220251221A1 (en) 2022-08-11
WO2019092181A1 (en) 2019-05-16
TW201922785A (zh) 2019-06-16
JP2021502116A (ja) 2021-01-28
SG11202004172UA (en) 2020-06-29
CN111954680B (zh) 2024-03-15

Similar Documents

Publication Publication Date Title
JP7603738B2 (ja) Ｉｌ２ｒベータ／共通ガンマ鎖抗体
US11142574B2 (en) Anti-TIM-3 antibodies
US11072659B2 (en) Anti-PD-1 antibodies
JP6908591B2 (ja) Ｉｌ２ｒベータ／共通ガンマ鎖抗体
US10435466B2 (en) Anti-TIM-3 antibodies
WO2020094834A1 (en) Il2rbeta/common gamma chain antibodies
JP7425604B2 (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
KR20190015715A (ko) 항-ctla-4 항체
WO2020094836A1 (en) Il2rbeta/common gamma chain antibodies
HK40084551A (en) Il2rbeta/common gamma chain antibodies
HK1250996B (en) Il2rbeta/common gamma chain antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230323

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230421

R150 Certificate of patent or registration of utility model

Ref document number: 7269249

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150